Vimarsana
Biggest News Aggregation in the World

Page 10 - Altimmune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Altimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Altimmune Today - Breaking & Trending Today

JMP Securities Reiterates "Market Outperform" Rating for Altimmune (NASDAQ:ALT) - Vimarsana News

JMP Securities Reiterates "Market Outperform" Rating for Altimmune (NASDAQ:ALT)

JMP Securities reiterated their market outperform rating on shares of Altimmune (NASDAQ:ALT – Get Rating) in a report released on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Several other research analysts have also weighed in on the stock. Evercore ISI upped their price objective on shares of Altimmune from […]

Altimmune : Evercore ISI NASH Renaissance 2023 Presentation - Vimarsana News

Altimmune : Evercore ISI NASH Renaissance 2023 Presentation

NASH Renaissance 2023 Pemvidutide-Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity Evercore ISI Research... | March 30, 2023

Altimmune, Inc. (NASDAQ:ALT) Director Buys $38,430.00 in Stock - Vimarsana News

Altimmune, Inc. (NASDAQ:ALT) Director Buys $38,430.00 in Stock

Altimmune, Inc. (NASDAQ:ALT – Get Rating) Director David Drutz purchased 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were bought at an average cost of $4.27 per share, for a total transaction of $38,430.00. Following the completion of the acquisition, the director now directly owns 29,484 […]

ALTIMMUNE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Vimarsana News

ALTIMMUNE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On March 27, 2023, the Board of Directors of Altimmune, Inc. appointed... | March 27, 2023

Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Analysts - Vimarsana News

Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 […]